Sutro Biopharma (STRO) Price & Analysis

Compare

689 Followers

STRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.52 - $5.17

Previous CloseN/A

Volume326.60K

Average Volume (3M)853.02K

Market Cap

$68.02M

Enterprise Value$74.93M

Total Cash (Recent Filing)$248.97M

Total Debt (Recent Filing)$21.40M

Price to Earnings (P/E)―

Beta3.79

Next Earnings

Nov 05, 2025

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding84,461,365

10 Day Avg. Volume313,427

30 Day Avg. Volume853,019

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.10

Enterprise Value/Revenue1.13

Enterprise Value/Gross Profit29.43

Enterprise Value/Ebitda-0.37

Forecast

1Y Price Target

$1.60

Price Target Upside100.00% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe restructuring extends the cash runway into at least the fourth quarter of 2026, allowing Sutro to focus on its pipeline of preclinical next-gen ADCs.

Partnerships And CollaborationsSutro Biopharma partnered ROR1 ADC STRO-003 with Ipsen and is developing two immunostimulatory ADCs with Astellas, which could bring in over $1.6 billion in milestones plus royalties.

Preclinical DataSutro Biopharma presented positive preclinical data for STRO-004, showing potent antitumor activity in several cancer models and a wider therapeutic window compared to first-generation TF ADCs.

Bears Say

Clinical RisksThere is a risk that Sutro Biopharma's drugs may fail in the clinic, and the company will likely require additional capital.

Safety ChallengesPast safety challenges with TF-targeted ADCs raise questions about whether the DAR8 exatecan format can achieve a clinically acceptable therapeutic index.

Workforce ReductionSutro will deprioritize luvelta and reduce its workforce by approximately 50%.

Sutro Biopharma News

Sutro Biopharma enters research collaboration with FDA for ADC standards

Sutro Biopharma (STRO) entered into a collaboration with the U.S. Food and Drug Administration to develop reference materials...

19d ago

STRO

Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Hold rating on Sutro Biopharma. The associated price...

2d ago

STRO

Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results

Sutro Biopharma ( ($STRO) ) has released its Q2 earnings. Here is a breakdown of the information Sutro...

2d ago

STRO

Sutro Biopharma Faces NASDAQ Non-Compliance Notice

Sutro Biopharma ( ($STRO) ) has provided an announcement. On June 20, 2025, Sutro Biopharma received a notice...

2M ago

STRO

Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($STRO) ), ( ($SRPT) ), ( ($INCY) ), ( ($SIG)...

2M ago

SIG

WIX

Piper upgrades Sutro Biopharma to Overweight on attractive valuation

Piper Sandler last night upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of...

2M ago

STRO

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of $2. Published...

2M ago

STRO

Sutro Biopharma Adopts Key Proposals at Annual Meeting

Sutro Biopharma ( ($STRO) ) just unveiled an announcement. On June 6, 2025, Sutro Biopharma held its 2025...

2M ago

STRO

Sutro Biopharma appoints Greg Chow as CFO

Sutro Biopharma (STRO) announced the appointment of Greg Chow as CFO, effective June 2, 2025. Chow most recently...

2M ago

STRO

Sutro Biopharma price target lowered to 80c from $1 at BofA

BofA lowered the firm’s price target on Sutro Biopharma (STRO) to 80c from $1 and keeps an Underperform...

3M ago

STRO

Sutro Biopharma Reports Q1 2025 Earnings and Restructuring

Sutro Biopharma ( ($STRO) ) has released its Q1 earnings. Here is a breakdown of the information Sutro...

3M ago

STRO

Sutro Biopharma: Hold Rating Amid Strategic Transition and Preclinical Focus

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Hold rating on Sutro Biopharma (STRO – Research Report) today...

3M ago

STRO

Sutro Biopharma: Hold Rating Amid Promising ADC Advancements and Strategic Restructuring

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Hold rating on Sutro Biopharma (STRO – Research...

3M ago

STRO

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

ALT

CLLS

STRO FAQ

What was Sutro Biopharma Inc’s price range in the past 12 months?

Sutro Biopharma Inc lowest stock price was $0.52 and its highest was $5.17 in the past 12 months.

What is Sutro Biopharma Inc’s market cap?

Sutro Biopharma Inc’s market cap is $68.02M.

When is Sutro Biopharma Inc’s upcoming earnings report date?

Sutro Biopharma Inc’s upcoming earnings report date is Nov 05, 2025 which is in 87 days.

How were Sutro Biopharma Inc’s earnings last quarter?

Sutro Biopharma Inc released its earnings results on Aug 07, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.382 by $0.242.

Is Sutro Biopharma Inc overvalued?

According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sutro Biopharma Inc pay dividends?

Sutro Biopharma Inc does not currently pay dividends.

What is Sutro Biopharma Inc’s EPS estimate?

Sutro Biopharma Inc’s EPS estimate is -0.37.

How many shares outstanding does Sutro Biopharma Inc have?

Sutro Biopharma Inc has 84,461,365 shares outstanding.

What happened to Sutro Biopharma Inc’s price movement after its last earnings report?

Sutro Biopharma Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.382. Following the earnings report the stock price went down -2.439%.

Which hedge fund is a major shareholder of Sutro Biopharma Inc?

Currently, no hedge funds are holding shares in STRO

Sutro Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-347.64%

Trailing 12-Months

Asset Growth

-46.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sutro Biopharma Inc

Sutro Biopharma, Inc. (STRO) is a biotechnology company focused on developing and manufacturing next-generation oncology therapeutics. The company specializes in the development of antibody-drug conjugates (ADCs), bispecific antibodies, and other protein therapeutics for cancer treatment. Sutro leverages its proprietary cell-free protein synthesis platform, XpressCF+, to create complex biologics that can target cancer cells more precisely, offering potentially improved therapies for patients.

Sutro Biopharma (STRO) Earnings & Revenues

Historic Earnings Reports

STRO Earnings Call

Q4 2025

0:00 / 0:00

STRO Stock 12 Month Forecast

Average Price Target

$1.60

▲(100.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,0.9015384615384616,0.9930769230769232,1.0846153846153848,1.1761538461538463,1.267692307692308,1.3592307692307692,1.4507692307692308,1.5423076923076924,1.633846153846154,1.7253846153846155,1.816923076923077,1.9084615384615384,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,0.8707692307692309,0.9315384615384616,0.9923076923076923,1.0530769230769232,1.113846153846154,1.1746153846153846,1.2353846153846155,1.2961538461538462,1.356923076923077,1.4176923076923078,1.4784615384615385,1.5392307692307692,{"y":1.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,0.8092307692307693,0.8084615384615386,0.8076923076923077,0.806923076923077,0.8061538461538462,0.8053846153846155,0.8046153846153846,0.8038461538461539,0.8030769230769231,0.8023076923076924,0.8015384615384615,0.8007692307692308,{"y":0.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >